14:44 uur 11-12-2018

Quotient Sciences Organiseert Integrated Translational Pharmaceutics® programma in de VS met Druggability Technologies

NOTTINGHAM, Engeland –(BUSINESS WIRE)– Quotient Sciences, een toonaangevende organisatie voor geneesmiddelenontwikkeling en Druggability Technologies (DRGT), een gespecialiseerd farmaceutisch bedrijf, kondigden vandaag een samenwerking aan om gebruik te maken van Quotient’s geïntegreerde Translational Pharmaceutics® platform om de ontwikkeling van DRGT-46, een nieuwe, snelwerkende formulering van celecoxib met gebruikmaking van eigen super-API composities ontwikkeld door DRGT, te bevorderen. Dit zal Quotient’s eerste Translational Pharmaceutics programma zijn dat geleverd wordt vanuit de operationele faciliteiten in de VS.

Binnen het werkprogramma heeft DRGT toegang tot Quotient’s unieke Translational Pharmaceutics platform. Dit omvat de ontwikkeling van amorfe spray-dried formules en de productie van GMP-klinische studies in Philadelphia, gevolgd door klinische dosering en smaakbeoordeling in de klinische farmacologische eenheid van Quotient in Miami. Het programma is volledig adaptief, wat DRGT in staat zal stellen om het geneesmiddel te optimaliseren in reactie op nieuwe klinische gegevens. Quotiënt zal vervolgens het geselecteerde product naadloos opschalen ter ondersteuning van centrale patiëntentests.

Quotient Sciences Conducts Integrated Translational Pharmaceutics® Program in U.S. with Druggability Technologies

NOTTINGHAM, England–(BUSINESS WIRE)– Quotient Sciences, a leading drug development services organization, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities.

Within the program of work, DRGT is accessing Quotient’s unique Translational Pharmaceutics platform. This involves the development of amorphous spray-dried formulations and GMP clinical trial manufacturing in Philadelphia followed by clinical dosing and taste assessment at Quotient’s clinical pharmacology unit in Miami. The program is fully adaptive, which will enable DRGT to optimize the drug product in response to emerging clinical data. Quotient will then seamlessly scale up the selected product to support pivotal patient trials.

Translational Pharmaceutics transforms the traditional model of outsourcing to disparate contract CDMOs and CROs by integrating formulation development, real-time adaptive GMP manufacturing and clinical research. It is proven to accelerate development timelines and reduce overall costs and has been applied in over 350 programs for customers worldwide. In 2017, Quotient established the capability to run Translational Pharmaceutics programs in the U.S. Following a Critical Path Innovation Meeting with the FDA’s Office of Translational Sciences, and meetings with local institutional review boards, Quotient is now delivering programs in the U.S.

“We have significantly expanded our CDMO and CRO operations in the U.S. and are now performing integrated programs in the world’s largest R&D market,” said Mark Egerton, Ph.D., CEO of Quotient. “This offers significant advantages to our customers. We are delighted to support DRGT on accelerating DRGT-46 as a new treatment for acute and chronic pain.”

Gábor Heltovics, CEO of DRGT, added, “We are very pleased to be working with Quotient on this accelerated development project with our proprietary super-API technology. Quotient’s tight integration of formulation, manufacturing and clinical research services has enabled DRGT to execute an efficient development plan with a single outsourcing partner and, most importantly, reduce our time to market.”

Quotient’s comprehensive drug product expertise spans all types of oral dosage forms, a broad range of solubilization technologies and high potency handling capabilities.

About Quotient Sciences

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, delivers innovative, customized solutions for over 150 pharmaceutical and biotech customers through both individual and integrated services. Quotient has more than 800 employees across six operating sites in the U.K. and U.S. Visit quotientsciences.com.

Contacts

Jane Byram
SCORR Marketing
+1 (512) 626-2758
jane@scorrmarketing.com

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr